Prometheus Licenses Colal-Pred From Alizyme

Prometheus Laboratories Inc., a specialty pharmaceutical company, announced that it has entered into an exclusive license agreement to develop and commercialize Colal-Pred for gastrointestinal diseases or other applications in North America from Alizyme Therapeutics Limited, a wholly owned subsidiary of Alizyme plc.
Earthtimes